GlassScriptPhysician profile
James Gordon Kantor
NPI 1255428629
$525.02
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $151 · 2021: $106.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $104.14 | 2019-2020 | |
| Kaleo, INC. | $87.20 | 2019-2020 | |
| Tris Pharma INC | $79.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $68.19 | 2019-2020 | |
| Genentech USA, INC. | $65.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.41 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $28.84 | 2019 | |
| Cranial Technologies, INC | $27.58 | 2021 | |
| Shire North American Group INC | $14.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kantor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.